Edwards Lifesciences Corporation
EW
$79.33
$0.020.03%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.94% | 2.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.94% | 2.32% | |||
| Cost of Revenue | 3.22% | 11.14% | |||
| Gross Profit | 1.60% | 0.19% | |||
| SG&A Expenses | -5.21% | 16.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 15.86% | -201.34% | |||
| Total Operating Expenses | -2.82% | 7.48% | |||
| Operating Income | 15.82% | -10.25% | |||
| Income Before Tax | 11.23% | -3.15% | |||
| Income Tax Expenses | 55.88% | 10.81% | |||
| Earnings from Continuing Operations | 5.39% | -4.72% | |||
| Earnings from Discontinued Operations | -118.32% | -98.55% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 23.08% | -7.14% | |||
| Net Income | -7.16% | -87.44% | |||
| EBIT | 15.82% | -10.25% | |||
| EBITDA | 12.61% | -7.53% | |||
| EPS Basic | -6.70% | -87.29% | |||
| Normalized Basic EPS | 16.22% | -15.06% | |||
| EPS Diluted | -7.04% | -87.29% | |||
| Normalized Diluted EPS | 16.19% | -15.04% | |||
| Average Basic Shares Outstanding | -0.49% | -1.24% | |||
| Average Diluted Shares Outstanding | -0.46% | -1.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||